Please login to the form below

axitinib

This page shows the latest axitinib news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Bavencio (avelumab), in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), has been recommended as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) – the most

Latest news

NICE turns down Keytruda/Inlyta combo for kidney cancer

However, the long-term benefit of checkpoint inhibitor Keytruda (pembrolizumab) and tyrosine kinase inhibitor Inlyta (axitinib) in these patients is uncertain, which makes it hard to estimate its cost-effectiveness, according
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

Bavencio is also approved for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel cell carcinoma, and in combination with tyrosine kinase inhibitor Inlyta (axitinib) as
Aveo’s tivozanib is knocked back by FDA once again

inhibitors and VEGF inhibitors – in particular Pfizer’s VEGF inhibitor Inlyta (axitinib) – emerge as a strong therapeutic option.
Pfizer raises forecast following growth of biopharma business

Inlyta (axitinib) has also seen its revenues increase 98% to $139m, thanks to recent FDA approvals for the comination of the drug with Bavencio (avelumab) and Keytruda (pembrolizumab).
MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups. MSD’s Keytruda in combination with Inlyta (axitinib) has won European Commission (EC) approval in the first-line treatment of the most ... The European approval of Keytruda with axitinib

More from news
Approximately 5 fully matching, plus 34 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Route 66: can remote working put two-thirds of us back on the road to engaged employment?: Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals: Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....